678 related articles for article (PubMed ID: 25439967)
1. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
[TBL] [Abstract][Full Text] [Related]
2. Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment.
Gungor S; Rezigue M
Curr Drug Metab; 2017; 18(5):454-468. PubMed ID: 28228078
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.
Rahman M; Beg S; Sharma G; Saini S; Rub RA; Aneja P; Anwar F; Alam MA; Kumar V
Recent Pat Antiinfect Drug Discov; 2016; 11(1):3-15. PubMed ID: 27193030
[TBL] [Abstract][Full Text] [Related]
4. Role of Apoptotic-targeted Phytoconstitutent-loaded Antipsoriatic Nanobiocomposites.
Singh Patel P; Srivastava R; Panchawat S
Recent Pat Nanotechnol; 2024; 18(2):220-236. PubMed ID: 36725825
[TBL] [Abstract][Full Text] [Related]
5. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS).
Sala M; Elaissari A; Fessi H
J Control Release; 2016 Oct; 239():182-202. PubMed ID: 27381248
[TBL] [Abstract][Full Text] [Related]
6. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.
Gupta M; Agrawal GP; Vyas SP
Curr Mol Med; 2013 Jan; 13(1):179-204. PubMed ID: 22834834
[TBL] [Abstract][Full Text] [Related]
7. Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier.
Ramanunny AK; Wadhwa S; Thakur D; Singh SK; Kumar R
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):418-433. PubMed ID: 32496998
[TBL] [Abstract][Full Text] [Related]
8. An Overview on Promising Nanotechnological Approaches for the Treatment of Psoriasis.
Pandey K; Nimisha
Recent Pat Nanotechnol; 2020; 14(2):102-118. PubMed ID: 32013854
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery.
Rahman M; Beg S; Ahmad MZ; Kazmi I; Ahmed A; Rahman Z; Ahmad FJ; Akhter S
Curr Drug Targets; 2013 Jun; 14(6):708-22. PubMed ID: 23531113
[TBL] [Abstract][Full Text] [Related]
10. A Promising Approach of Dermal Targeting of Antipsoriatic Drugs
Tripathi D; Srivastava M; Rathour K; Rai AK; Wal P; Sahoo J; Tiwari RK; Pandey P
Drug Metab Bioanal Lett; 2023; 16(2):89-104. PubMed ID: 37534794
[TBL] [Abstract][Full Text] [Related]
11. Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis.
Saleem S; Iqubal MK; Garg S; Ali J; Baboota S
Expert Opin Drug Deliv; 2020 Jun; 17(6):817-838. PubMed ID: 32315216
[TBL] [Abstract][Full Text] [Related]
12. Recent Advancements in Novel Formulations of Anti-psoriatic Agents for Effective Delivery: Clinical Importance and Patent Survey.
Dadwal N; Kurmi BD; Singh D; Singh A
Recent Pat Nanotechnol; 2024; 18(3):259-277. PubMed ID: 37264655
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
14. Modulating angiogenesis with integrin-targeted nanomedicines.
Duro-Castano A; Gallon E; Decker C; Vicent MJ
Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
[TBL] [Abstract][Full Text] [Related]
15. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors.
Katare OP; Raza K; Singh B; Dogra S
Indian J Dermatol Venereol Leprol; 2010; 76(6):612-21. PubMed ID: 21079304
[TBL] [Abstract][Full Text] [Related]
16. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity.
Raza K; Singh B; Lohan S; Sharma G; Negi P; Yachha Y; Katare OP
Int J Pharm; 2013 Nov; 456(1):65-72. PubMed ID: 23973754
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
18. Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview.
Dadwal A; Mishra N; Narang RK
Curr Pharm Des; 2018; 24(33):3934-3950. PubMed ID: 30387390
[TBL] [Abstract][Full Text] [Related]
19. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches.
Pradhan M; Singh D; Singh MR
J Control Release; 2013 Sep; 170(3):380-95. PubMed ID: 23770117
[TBL] [Abstract][Full Text] [Related]
20. Exploring the potential of nanocarriers in antipsoriatic therapeutics.
Shaif M; Kushwaha P; Usmani S; Pandey S
J Dermatolog Treat; 2022 Nov; 33(7):2919-2930. PubMed ID: 35729857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
